Centro Hospitalar de Setubal E.P.E.
- Address
- lock Available on a paid plan
Cardiovascular Research
The Centro Hospitalar de Setubal is leading trials that aim to lower the incidence of major adverse cardiovascular events and improve lipid profiles in high‑risk patients.
- inclisiran for ASCVD risk reduction
- olpasiran targeting elevated Lp(a)
- primary prevention strategies for atherosclerotic disease
- assessment of coronary heart disease outcomes
With 19 investigators, the site in Setúbal, Portugal, focuses on innovative therapies to protect heart health across Europe.
Immune System Research
Studies at the hospital explore new options for patients with autoimmune disease, particularly focusing on lupus nephritis.
- Zetomipzomib in active lupus nephritis
- investigating novel immunomodulators
- exploring treatment for Class III/IV renal involvement
- advancing care for autoimmune kidney disease
The multidisciplinary team of 19 investigators collaborates to improve outcomes for immune‑mediated conditions.
Oncology & Melanoma Studies
The oncology department evaluates cutting‑edge therapies for unresectable or metastatic melanoma, comparing novel agents with established immunotherapies.
- ABP 206 versus nivolumab
- first‑line treatment for advanced melanoma
- evaluating response in patients without prior systemic therapy
- enhancing outcomes for metastatic skin cancer
Conducted by 19 dedicated investigators, the trials at Centro Hospitalar de Setubal contribute to global advances in cancer care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 10 therapeutic areas and 15 of 45 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 43 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1Janssen Cilag International2active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG4trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 84 other sites in Portugal
Therapeutic Area Benchmark — Portugal
Select a therapeutic area to compare against other sites in Portugal.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Portugal
Market Share
Country: Portugal
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centro Hospitalar de Setubal E.P.E.
lock Showing 1 of 24 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b, Randomized, Controlled Double-blind, Multicenter Study Comparing the Efficacy and Safety of Zetomipzomib (KZR-616) 30 mg or 60 mg with Placebo in Patients with Active Lupus Nephritis | Kezar Life Sciences Inc. | Phase II | Not Recruiting | Oct 2023 | Oct 2024 |
IMP list
lock Showing 1 of 45 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atogepant | 2 | Unknown | 2024-04-03 | 2025-03-05 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.